Experienced in Hepatic Venoocclusive Disease with Immunodeficiency

Dr. Richard A. Aplenc

Pediatric Hematology Oncology
Childrens Health Care Associates Inc
3401 Civic Ctr Blvd, 
Philadelphia, PA 
29 Years of Experience
Experienced in Hepatic Venoocclusive Disease with Immunodeficiency
Childrens Health Care Associates Inc
3401 Civic Ctr Blvd, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Aplenc is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Aplenc has been practicing medicine for over 29 years and is rated as an Experienced provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Childhood Acute Myeloid Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), Infantile Neutropenia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 240 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hepatic Venoocclusive Disease with Immunodeficiency.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

CHILDRENS HEALTH CARE ASSOCIATES INC
3401 Civic Ctr Blvd, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Aplenc has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: October 15, 2025
Intervention Type: Biological
Study Drugs: CART123 cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2025
Intervention Type: Biological
Study Drug: CD33-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
Enrollment Status: Completed
Publish Date: August 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

240 Total Publications

AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.
AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.
Journal: JCO oncology practice
Published: September 19, 2025
Similar Doctors
Elite in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Stephan A. Grupp
Pediatric Hematology Oncology
Elite in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Stephan A. Grupp
Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3535
Languages Spoken:
English
See accepted insurances

Stephan Grupp is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Grupp is rated as an Elite provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. His top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Leukemia, Neuroblastoma, and Bone Marrow Transplant.

Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Alix E. Seif
Pediatric Hematology Oncology
Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Alix E. Seif
Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
 (0.1 miles away)
215-590-3535
Languages Spoken:
English
See accepted insurances

Alix Seif is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Seif is rated as an Advanced provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hepatic Venoocclusive Disease with Immunodeficiency, Infantile Neutropenia, and Bone Marrow Transplant.

Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Caitlin W. Elgarten
Pediatric Hematology Oncology
Advanced in Hepatic Venoocclusive Disease with Immunodeficiency
Dr. Caitlin W. Elgarten
Pediatric Hematology Oncology
3401 Civic Center Blvd, The Children's Hospital Of Philadelphia - Gen Peds, 
Philadelphia, PA 
 (0.1 miles away)
215-590-2164
Languages Spoken:
English
See accepted insurances

Caitlin Elgarten is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Elgarten is rated as an Advanced provider by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. Her top areas of expertise are Infantile Neutropenia, Childhood Acute Myeloid Leukemia, Hepatic Venoocclusive Disease with Immunodeficiency, Bone Marrow Transplant, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aplenc's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile